Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMEO
2025-523690-41-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoint: Adverse events and laboratory assessments. Planned start Dec 2025; status: authorised.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-523690-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523690-41-00.